Podcast

Managing Early-Stage HER2-Positive Breast Cancer

Author(s):

OncLive Staff

In the second segment, Dr Mahtani and colleagues discuss data from select clinical trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.

Related Videos
2 experts are featured in this series.
Sagar D. Sardesai, MBBS
DB-12
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Related Content
Joseph A. Sparano, MD, FACP
December 23rd 2024

Tailor-Made for a Lifelong Pursuit of Precision in Cancer Care

Jorge Cortes, MD
December 25th 2024

Exploring Luspatercept's Role in Anemia Management for Lower-Risk MDS: Insights From Dr. Jorge Cortes

Breast Cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
December 17th 2024

Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS

Onyee Chan, MD, hematologist/oncologist, Moffitt Cancer Center Magnolia Campus; Bradley D. Hunter, MD, medical director, Oncology, director, Immune Effector Cell Therapy, Intermountain Healthcare
December 24th 2024

Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD

Breast cancer / stock.adobe.com
December 16th 2024

Baseline ctDNA Is Associated With Larger Pathological Tumors in HR+ Early Breast Cancer

Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
December 15th 2024

Elacestrant Improves Real-World Time to Next Treatment or Treatment Discontinuation in ESR1+ HR+/HER2– Breast Cancer